Antibacterial Agents TRIZ Cases

Controlled evaporation removes selected volatile fractions from essential oil, concentrating activity against bacterial and fungal strains.

Separating antigen recognition from C1q recruitment addresses antibody-binding density and geometry limits on complement-mediated killing.

Multiple rhamnose molecules linked to antibodies recruit immune responses at cancer and pathogen targets while addressing resistance mechanisms.

Error-prone PCR and fermentation in Trichoderma reesei produce stable, low-hemolysis TrSub for feed additive applications.

Selective N-glycan trimming exposes conserved SARS-CoV-2 epitopes while preserving tertiary structure for broader variant protection.

A dual regimen pairs sirolimus with tetracyclines to manage immune response and block amyloid and prion protein formation in animals.

Omadacycline penetrates infected cells and lung tissue to support long-term mycobacterial treatment with fewer gastrointestinal side effects.

Kinetic isotope substitution slows secnidazole metabolism, extending its elimination half-life for lower-dose bacterial vaginosis treatment.

Modified furin cleavage sites help recombinant proteins regulate free TGF-β growth factor release while preserving signaling control.

Existing vaccines protect against serotype b but lack cross-protection; saccharide-carrier conjugates target H. influenzae serotypes a–f.

Poorly tolerated NTM therapies are addressed with nebulized liposomal amikacin that concentrates aminoglycoside delivery in the lungs.

Drug efflux pumps weaken antibiotics against resistant Gram-negative bacteria; piperazine derivatives inhibit them and restore combination activity.

Targeted cdtR mutations, including a 69-base pair deletion, reduce toxin expression while preserving gut colonization for protection against wildtype infection.

Monovalent TCRs can lack pMHC avidity; IgM or IgA multimerization creates multivalent binders for detection and immune modulation.

Mature P. aeruginosa biofilms resist conventional antibiotics; NAC disrupts the matrix so colistin can penetrate and eradicate embedded cells.

Varying aryl and other substituents around the core addresses limited scaffold activity with broad antifungal, antitubercular, antimalarial, and antitumor effects.

Microbiome sequencing compares the patient with relatives, affected peers, and pre-condition samples to guide transplantation and restore gastrointestinal balance.

CRISPR-Cas genome cutting targets microbial DNA to support rapid acute infection treatment with less frequent dosing.

This 8-residue amphiphilic AMP disrupts PSA membranes and causes calcium leakage, with a reported MIC of 3.13 μg/mL and low hemolysis.

Peptide compounds bind menaquinone directly, disrupt bacterial membranes, and inhibit multidrug-resistant bacteria, including M. tuberculosis.

Engineered LL-37-derived peptides disrupt bacterial membranes and inhibit resistance development in antibiotic-resistant biofilms.

Probiotic, honey, and other natural ingredients disperse pathogenic biofilms while supporting local immunity without antibiotic treatment.

Long NTM regimens with poor outcomes are addressed by combining epetraborole and ethambutol for potential treatment synergy.

Maceration followed by controlled heating coagulates watercress proteins, separating a liquid fraction for urease inhibitor extraction.

Beta-lactamase production can disable cefepime; crystalline boron-containing inhibitor forms support stable injectable treatment of resistant infections.

Antimicrobial peptides use alternative membrane-disruption mechanisms to target resistant bacteria and reduce biofilm formation.

C-Type Lectin domains help liposomes bind pathogen antigens, improving targeting while lowering drug exposure to animal cells.

By activating TRPA1 with fear-odor compounds, this case induces hypothermia, hypometabolism, and anti-inflammatory responses without cooling equipment.

Existing β-lactamase inhibitors can miss Class D and metallo-β-lactamases; intravenous Compound A with meropenem enhances activity against resistant bacteria.

Fusion proteins use half-life extension domains, anionic blocks, and cleavable linkers to activate peptides at disease sites and limit off-target toxicity.

Phosphate copolymers suppress pathogen virulence factors for infection treatment without significantly reducing beneficial bacteria.

A barrier-based separation process isolates PEGylated IL-2 by binding site, supporting IL-2Rβγ selectivity and fewer adverse reactions.

Purified bacteriophage compositions target bacterial infections while removing harmful impurities and reducing the inflammatory response.

Unfractionated Croton lechleri latex uses multiple natural compounds for broad antibacterial coverage in infected or colonized skin.

Single-domain antibodies can degrade in the stomach; a linked two-peptide construct preserves binding to pathogen components and toxins.